AFP – L3% and DCP as screening marker for a hepatocellular carcinoma in patients with cirrhosis of the liver

AFP – L3% and DCP as screening marker for a hepatocellular carcinoma in patients with cirrhosis of the liver - HCC - Surveillance- Trial

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00000811

Enrollment

600

Registered

2011-05-03

Start date

2010-06-10

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C22.0 K74.6

Interventions

Group 1: During the regular screening for HCC nodules serum samples of patients with cirrhosis of the liver are taken in order to perform the measurement of AFP, AFP-L3 and DCP every 6 months. The dur

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: - age between 18 and 80 - cirrhosis of the liver confirmed by ultrasound or other imaging techniques (MRI, CT) or biopsy - at the time of enrollment: no HCC- suspected lesion detectable in the liver

Exclusion criteria

Exclusion criteria: other liver tumors or metastasis or tumor of unknown origin

Design outcomes

Primary

Measure	Time frame
- evaluation of the diagnostic usefulness of AFP, AFP-L3 and DCP alone and in combination (sensitivity, specifity) - evaluation of the time of a positive tumor marker value in relation to the radiological detection of a tumor nodule (measurement of these markers every 6 months, ultrasound every 6 months)	—

Secondary

Measure	Time frame
- differences in these tumor markers between men and women - differences between etiologies	—

Countries

Germany

Contacts

Public ContactMichael Schultheiß

UKL Freiburg, Med. Klinik II

michael.schultheiss@uniklinik-freiburg.de0761-270-34010

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026